This way, the use of a small peptide aptamer allows the target of one of the two DNA binding domains of RAD52 and, consequently, inhibits its DNA binding capacity, promoting the accumulation of deleterious DBSs in leukemia cells. This evidence concerns the gene RAD52 and leukemia.